Loading
Latest filing published 13 Oct 2015 for Anthera Pharmaceuticals Inc, €6,526.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Debra Odink is a declared insider of Anthera Pharmaceuticals Inc, with filings sourced from SEC (Form 4). In total, 22 filings cover trades dated from 4 March 2010 to 12 October 2015.
In open-market terms, that means 1 purchase worth €3,153 on one side and 5 sales worth €38k on the other. Sales outweigh purchases by €35k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 10 share grants and 1 option exercise. So far in 2015, the count stands at no purchases and 1 sale.
The latest filing, published on 13 October 2015, reports an open-market sale of €6,526 in Anthera Pharmaceuticals Inc. The most recent open-market purchase was published on 24 September 2010, 5,873 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations